Pharmacotherapy of Child and Adolescent Psychiatric Disorders (inbunden)
Fler böcker inom
Format
Inbunden (Hardback)
Språk
Engelska
Antal sidor
480
Utgivningsdatum
2012-02-03
Upplaga
3 ed
Förlag
Wiley-Blackwell
Medarbetare
Ryan, Neal
Illustrationer
Illustrations
Dimensioner
251 x 175 x 25 mm
Vikt
863 g
Antal komponenter
1
Komponenter
69:B&W 6.69 x 9.61 in or 244 x 170 mm (Pinched Crown) Case Laminate on White w/Gloss Lam
ISBN
9780470973769
Pharmacotherapy of Child and Adolescent Psychiatric Disorders (inbunden)

Pharmacotherapy of Child and Adolescent Psychiatric Disorders

Inbunden,  Engelska, 2012-02-03
1125
  • Skickas från oss inom 7-10 vardagar.
  • Fri frakt över 249 kr för privatkunder i Sverige.
Finns även som
Visa alla 2 format & utgåvor
This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications. Third edition of the first ever book published on pediatric psychopharmacology from renowned editors. Incorporates current developments with regard to SSRIs, their indications and their safety issues, including possible associated suicidal behavior. Addresses concerns about cardiovascular side effects of the new stimulant medications available, and compares to other FDA-approved medications for ADHD. Features many tables, figures and pictorials, making it highly accessible and reader friendly.
Visa hela texten

Passar bra ihop

  1. Pharmacotherapy of Child and Adolescent Psychiatric Disorders
  2. +
  3. The Indoctrinated Brain

De som köpt den här boken har ofta också köpt The Indoctrinated Brain av Michael Nehls (inbunden).

Köp båda 2 för 1484 kr

Kundrecensioner

Har du läst boken? Sätt ditt betyg »

Fler böcker av författarna

Recensioner i media

Pharmacotherapy of Child and Adolescent Psychiatric Disorders is a book to have available on your desk, not just in your library. It provides ready access to the wealth of practical information and insight for the range of health and mental health professionals. It is highly recommended for trainees and anyone who is prescribing psychotropic medications to the pediatric population and young adults. (Journal of Clinical Psychiatry, 7 July 2012)

Övrig information

David Rosenberg MD, Miriam L. Hamburger Endowed Chair of Child Psychiatry and Professor & Chief of Child Psychiatry and Psychology at Wayne State University and the Children's Hospital of Michigan, Detroit, MI , USA Samuel Gershon MD, Emeritus Professor of Psychiatry, University of Pittsburgh, PA, USA

Innehållsförteckning

List of Contributors, xv Foreword, xix Chapter 1 Historical Perspectives on Child and Adolescent Psychopharmacology, 1 Samuel Gershon References, 4 Chapter 2 Pharmacoepidemiology of Psychotropic Medications in Youth, 7 Daniel J. Safer & Julie Magno Zito Introduction, 7 Prevalence and trends for medications prescribed for ADHD, 8 Nonstimulant medications for ADHD, 11 Antidepressant medication, 11 Antipsychotic medication, 13 Alpha-agonists, 14 Anticonvulsant "mood stabilizers", 15 Concomitant psychotropic medication, 15 Preschool psychotropic medication use, 17 International patterns of psychotropic medication for youth, 17 Conclusion, 18 References, 18 Chapter 3 Off-Label Prescribing of Drugs in Child and Adolescent Psychiatry, 25 C. Lindsay DeVane Introduction, 25 Extent of off-label prescribing, 27 Need for psychoactive drug treatments for children and adolescents, 31 Legislation supporting pediatric drug development, 33 Recommendations to follow when considering off-label prescribing, 35 References, 36 Chapter 4 The Use of Generic Drugs in Pediatric Psychopharmacology, 39 Richard I. Shader & Christopher-Paul Milne What is a generic drug?, 39 Why are we discussing generic drugs?, 39 Basic requirements for generic drugs, 40 The status of regulations regarding generic drugs and children, 41 Abbreviated new drug application (ANDA) requirements, 42 Pediatric assessments of adult drugs (history up to current status), 43 Best Pharmaceuticals for Children Act, 44 Pediatric Research Equity Act, 45 Intersection of requirements for generics and pediatric assessment, 46 Future directions, 48 Concluding thoughts, 49 References, 49 Chapter 5 Psychoactive Drug Use in Children: Basic Concepts in Clinical Pharmacology, 51 David J. Edwards Introduction, 51 Basic concepts in pharmacokinetics, 52 Dosing considerations for psychoactive drugs in children, 55 Summary, 60 References, 60 Chapter 6 Psychostimulants, 65 Steven R. Pliszka Introduction, 65 Epidemiology of stimulant use, 66 Structure and biochemical mechanism of action, 66 Neuroimaging studies of stimulant effects, 67 Studies of short-term efficacy, 72 Studies of long-term efficacy, 76 Clinical use, 79 Common side-effects, 84 Cardiovascular safety issues, 86 Growth suppression, 88 Substance use and diversion, 88 Comparison with nonstimulant treatment, 89 Treatment of comorbidity, 92 Pharmacogenetics, 93 Conclusions, 94 References, 94 Chapter 7 Tricyclic Antidepressants and Monoamine Oxidase Inhibitors for the Treatment of Child and Adolescent Psychiatric Disorders, 105 Charlotte M. Heleniak, Tejal Kaur, Kareem D. Ghalib & Moira A. Rynn Tricyclic antidepressants (TCAs), 105 Drug interactions, contraindications, 116 Monoamine oxidase inhibitors (MAOIs), 117 General summary, 122 References, 123 Chapter 8 Selective Serotonin Reuptake Inhibitors (SSRIs), 131 Dara Sakolsky & Boris Birmaher Pharmacokinetics, 131 Initiation and titration, 133 Indications and efficacy, 134 Adverse effects, 146 Withdrawal, 149 References, 149 Chapter 9 Novel (Atypical) Antidepressants, 155 Heidi R. Bruty, Graham J. Emslie & Paul Croarkin Novel (atypical) antidepressants, 155 General overview, 155 Bupropion, 157 Duloxetine, 162 Mirtazapine, 164 Trazodone, 166 Venlafaxine, 170 Desvenlafaxine, 173 Alternative treatments, 174 Summary, 175 References, 176 Chapter 10 Antipsychotic Agents, 181 Brieana M. Rowles, John L. Hertzer & Robert L. Findling Introduction, 181 Chemical properties, 182 Typical antipsychotics, 183 Atypical antipsychotics, 186 Ethical issues: treatment of at-risk populations, 212 Conclusions, 213 References, 213 Chapter 11 Lithium, 221 Garrett M. Sparks & David A. Axelson Introduction, 221 Pharmacology, 222 Potential mechanisms of action, 222 Evidence for the use